Curetopia has secured $1.77 million in funding to promote the treatment of rare diseases through a decentralized biotechnology model that utilizes Solana.
Fundraising efforts supported by more than 1,000 individual contributors underscore the growing momentum of the Decentralized Science Science (DESCI) sector, particularly amidst a sustained US freeze of traditional funding sources such as the National Institutes of Health (NIH) and the National Science Foundation (NSF).
Kiletopia DAO was launched on Bioprotocol with support from Binance. Using blockchain-based crowdfunding, Kiletopia allows patients with rare diseases and researchers to collaborate and fund drug development projects and share ownership of the resulting treatment through tokenization.
Curetopia recently identified a potential treatment for AARS2 progressive cleroencephalosis, a fatal mitochondrial disease that lacks approved treatments. This finding arising from the screening of 8,500 reusable compounds via yeast models represents one of the first examples of a crypto-assisted research project that could reach commercialization.
Curetopia is currently filing a provisional patent for this discovery. The proceeds from subsequent commercialization will be reinvested in DAO.
Curetopia’s operational model incorporates direct engagement with the patient community, a strategy advocated by founders Dr. Ethan Perlstein, Harvard PhD and former Y-combinator participants. Perlstein previously demonstrated cost-effective clinical development by moving into phase 3 trials to treat rare diseases at $5 million, specifically lower than traditional drug routes.
Perlstein emphasized that decentralized drug development can directly affect patients and families with rare diseases on therapeutic development, breaking the cycle of neglected research due to limited commercial incentives.
Participants in Curetopia’s decentralized trials will receive treatment tokens and will effectively become stakeholders of treatments that will help develop.
Utilizing drug reuse, tokenized intellectual property, and community-driven testing, Curetopia’s model aims to accelerate regulatory approval processes, significantly reducing both the time and financial costs associated with traditional drug development.
DAO recently partnered with CombinedBrain and Uravel Biosciences to provide drug screening services to organizations representing over 100 genetic neurodevelopmental disorders.
Focusing on drug reuse, Karetopia aims to take advantage of regulatory benefits such as FDA priority review vouchers and isolated drug designations.
